← Back to context

Comment by AbstractH24

18 hours ago

I recently heard Anthropic quietly setup its own bio lab.

That it’s plausible that they’ll move from selling tokens as their primary source of revenue to building frontier models to do cutting edge research, and using the research as their primary source of revenue rather than release the models. Because it’ll be far less of a race to the bottom than commodified tokens used by the general public.

Will be interesting to see how this all unfolds. (No pun intended, but there is a funny one there…)

Yea, I think that there's pretty much a ceiling with day-to-day models that have already been hit months ago. Maybe you need SOTA for reviews, high-level planning, or research, but long running tasks like writing out a feature, testing, getting feedback and making refactors can be done for low-end models (like luna). And the margins on those models are basically evaporating.

apparently big labs are also pitching profit sharing arrangements to biopharma companies in exchange for privileged access to the top internal above-the-api capability models .... repeat this in every industrial vertical and it could turn out that much denied Dario claim may as well have been true for all intents and purposes

  • I mean its what universities have done for years haven't they?

    Never really wondered what financial relationship between research hospitals that participate in drug trials and pharma companies is, but now I'm wondering...

Yeah, I hope so as well. I want to see this tech being used for good stuff and not just spam and inducing fear ...

So they're already threatening their customers Amazon-style?

Excellent. Now every pharma company, plus any kind of company that wants to own a market through innovation, will need a "world-class" AI research team that actually has spectacular AI budgets.

  • Pretty much

    The analogy to Amazon works on all sorts of levels. From Amazon.com vs AWS to Amazon.com vs sellers